Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONStandard

YUTREPIA

TREPROSTINIL SODIUM

Standard Dose
EQ 0.106MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview YUTREPIA is listed in Drugs@FDA under application 213005 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL SODIUM Form and strength POWDER;INHALATION - EQ 0.106MG BASE/INH Sponsor LIQUIDIA TECH Submission history Latest submission status date: 2025-05-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview YUTREPIA is listed in Drugs@FDA under application 213005 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL SODIUM Form and strength POWDER;INHALATION - EQ 0.106MG BASE/INH Sponsor LIQUIDIA TECH Submission history Latest submission status date: 2025-05-23 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.